Tetrandrine - CBA Pharma

Drug Profile

Tetrandrine - CBA Pharma

Alternative Names: CBT-1; NSC-77037

Latest Information Update: 25 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CBA Pharma
  • Developer CBA Pharma; National Cancer Institute (USA); Sarcoma Alliance for Research through Collaboration
  • Class Alkaloids; Antiarrhythmics; Antihypertensives; Antimalarials; Antineoplastics; Benzylisoquinolines; Small molecules
  • Mechanism of Action P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Cancer
  • Phase III Non-small cell lung cancer
  • Phase II Acute myeloid leukaemia; Breast cancer; Cervical cancer; Gastrointestinal cancer; Head and neck cancer; Lung cancer; Multiple myeloma; Ovarian cancer; Prostate cancer; Renal cancer; Small cell lung cancer; Solid tumours
  • Preclinical Sarcoma

Most Recent Events

  • 29 Dec 2016 CBA Pharma plans a phase I trial for Sarcoma (Adjunctive treatment, Metastatic disease, Second-line therapy or greater, Late-stage disease) in USA (PO) (NCT03002805)
  • 01 Dec 2016 Preclinical trials in Sarcoma in USA (PO) before December 2016 (NCT03002805)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top